

1912 Rt 35 S, Ste 203, Oakhurst, NJ 07755 **P** 732 389 1530 | **F** 732 389 0352 **Courier P** 732 508 9154 genesislaboratory.com

| Acc | ession Info (For Genesis Lab U | se) |
|-----|--------------------------------|-----|
| | | |
| | | |

| | | | | Primarius Pathology | | | |
|--|---|--|--|--|--|--|--|
| | Respiratory | Requisition | | | | | |
| Date Specimen Collected: | Time Specime | n Collected: | | | | | |
| Laboratory Use Only | | | | | | | |
| Accession Number | Date Received | | | ceived | | | |
| Practice NamePractice ID_ | | | Practice Contact In | | | | |
| Ordering Physicians | | | Address | | | | |
| | | | | Other | | | |
| | | | Pnone | Other | | | |
| Surgery Center Name | | Surgery Center | Information | | | | |
| Is this for a pre-operative procedure? | | Address | | | | | |
| Date of Procedure | | City, State, Zip | | | | | |
| Physician Performing Surgery | | | | Fax | | | |
| Physician Performing Surgery Fax | | Other | | | | | |
| Patient and Insurance Informatio (Currently Not Accepting) YOU MUST CHECK OFF ONE OF THE FOLLOWING: | n (Email Addre ng Medicaid or Man | ess is required aged Medicaid Pl | d for the patient ans - Contract Pending | to obtain results) | | | |
| Skilled Nursing Facility (Inpatient Nursing Home) | Assisted Livina | Employee Te | esting Self-Pav | Other | | | |
| First Name | Last Name | | | Middle Initial | | | |
| | ess Line 2 | | | StateZip_ | | | |
| | Phone | | | | | | |
| | er* | | | itity* | | | |
| Race* Ethnic | city* | | | ntation* | | | |
| Insured's Name Relations | | | | cial Security # | | | |
| Home Phone Cell Phone | | | | | | | |
| Primary Insurance | | | | | | | |
| Group # ID# | | roup # | ID# | | | | |
| Address | A | ddress | | | | | |
| City State Zip | C | ity | State | Zip | | | |
| I certify that I do not have insurance at the time of vis | it (F | Patient's Initials | | | | | |
| | Respiratory | Test Panels | | | | | |
| Nasal Swab OR Nasopharyngeal Swab: COVID-19 (SARS-CoV-2 PCR Assay) Only COVID-19 + Influenza A & B, and RSV Panel Focused Viral Pathogen** (Influenza A & B, RSV, Adenovirus, hMPV, Rhinovirus) Genesis Expanded Respiratory Pathogen Panel** | | | | | | | |
| ICD-10 Codes | | | | | | | |
| COVID-19 CODES ARE LISTED BELOW AND MUST BE CHEC | KED OFF | | | mmunodeficiency ICD-10 Codes | | | |
| J20.8 Acute bronchitis due to other specified organisms J22 Unspecified acute lower repiratory infection J80 Acute respiratory distress syndrome R05 Cough R06.02 Shortness of breath R50.9 Fever unspecified Z20.822 Asymptomatic or suspected COVID-19 exposure Z86.16 Personal history of COVID-19 J11.1 Flu Like Symptoms J12.89 Other viral pneumonia | J06.9 Acute uppe J12.82 Pneumonia M35.81 Multisyste | g cough reptococcus cal pharyngitis virus identified r for antibody responser respiratory infect a due to coronavirus em inflammatory sy | ion, unspecified s disease 2019 | D83.9 Common variable immunodeficiency, unspecified D83.8 Other common variable immunodeficiencies D81.9 Combined immunodeficiency, unspecified D81.89 Other combined immunodeficiencies | | | |
| This test is medically necessary for the diagnosis or detection of a disease, illness, impairment, symptom, syndrome or disorder. The results will determine my patient's medical management and treatment decisions. The person listed as the ordering provider is authorized by law to order the test(s) requested herein. | | | | | | | |
| | | zed by law to order th | e test(s) requested herein. Accessione | ripitials 1 | | | |
| Signature of Physician or Other Authorized NPI Provider (REQUIREI | 11 | Listo | Accessione | I II I | | | |

*Gender, Gender Identity, Race, Ethnicity, and Sexual Orientation are required by certain states and the CDC. **See Reverse Side For Details. ICD-10 Codes are listed for information purposes only. It is the provider's responsibility to order tests that are medically necessary and in the best interest of the patient.

Genesis Expanded Respiratory Pathogen Panel

Bacteria

Bordetella (parapertussis, bronchiseptica) Bordetella pertussis Chlamydophila pneumoniae Legionella pneumophila

Mycoplasma pneumoniae

Viruses

Adenovirus

Human Metapneumovirus (hMPV)

Coronavirus 229E Coronavirus HKU1 Coronavirus NL63 Coronavirus OC43

Enterovirus Influenza A H1-2009 Influenza A H3 Influenza A pan Influenza B Parainfluenza Virus 1
Parainfluenza Virus 2
Parainfluenza Virus 3
Parainfluenza Virus 4

Respiratory Syncytial Virus (RSV) A Respiratory Syncytial Virus (RSV) B

Rhinovirus

| Focused Viral Pathogen Panel | COVID-19 + Influenza A&B, and RSV Panel | Group A Streptococcus | | |
|--|--|---------------------------------|--|--|
| Influenza A Influenza B | COVID-19 (SARS-CoV-2) Influenza A | Streptococcus pyogenes | | |
| Respiratory Syncytial Virus (RSV) Adenovirus | Influenza B Respiratory Syncytial Virus (RSV) | COVID-19 ONLY | | |
| Human Metapneumovirus (hMPV) Rhinovirus | | COVID-19 (SARS-CoV-2 PCR Assay) | | |

COVID-19

Information about COVID-19 (SARS-CoV-2 PCR Assay)

PLEASE NOTE: Testing was performed using the Thermo Fisher TaqMan 2019-nCoV Assay Kit v1, TaqMan 2019-nCoV Control Kit v1 Test, TaqPath COVID-19 Combo Kit and/ or Panther Fusion® SARS-CoV-2 Assay Kit by real-time (RT) PCR. Positive results do not rule out co-infection with organisms not included in the Thermo Fisher TaqMan 2019-nCoV Assay Kit v1 and TaqMan 2019-nCoV Control Kit v1, TaqPath COVID-19 Combo Kit and/ or Panther Fusion® SARS-CoV-2 Assay Kit by real-time (RT) PCR. The agent detected may not be the definite cause of this disease. This assay is for in vitro diagnostic use under the FDA Emergency Use Authorization (EUA). This test is only authorized for the duration of time of the declaration and for the detection of SARSCoV-2 RNA virus and/ or diagnosis of COVID-19 infection under section 564 (b)(1) of the act, 21 U.S.C.360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.

A Positive result indicates the presence of SARS-CoV-2 RNA but does not exclude bacterial infection and/or coinfection with other viruses. The agent detected may not be the definitive cause of disease. This result should be combined with clinical observation, patient history, and epidemiological information for patient management decisions.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for treatment and other patient management decisions.

Negative results must be used in conjunction with clinical observation, patient history, and epidemiological information for patient management decisions.